Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Depreciation & Amortization (CF): 2023-2025

Historic Depreciation & Amortization (CF) for Guardian Pharmacy Services (GRDN) over the last 3 years, with Q3 2025 value amounting to $5.8 million.

  • Guardian Pharmacy Services' Depreciation & Amortization (CF) rose 1690.03% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 1248.64%. This contributed to the annual value of $19.8 million for FY2024, which is 843.48% up from last year.
  • Guardian Pharmacy Services' Depreciation & Amortization (CF) amounted to $5.8 million in Q3 2025, which was up 1690.03% from $5.5 million recorded in Q2 2025.
  • In the past 5 years, Guardian Pharmacy Services' Depreciation & Amortization (CF) ranged from a high of $5.8 million in Q3 2025 and a low of $4.7 million during Q4 2023
  • Its 3-year average for Depreciation & Amortization (CF) is $5.1 million, with a median of $5.1 million in 2024.
  • Per our database at Business Quant, Guardian Pharmacy Services' Depreciation & Amortization (CF) skyrocketed by 931.27% in 2024 and then surged by 1690.03% in 2025.
  • Over the past 3 years, Guardian Pharmacy Services' Depreciation & Amortization (CF) (Quarter) stood at $4.7 million in 2023, then increased by 9.31% to $5.2 million in 2024, then increased by 13.29% to $5.8 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $5.8 million for Q3 2025, versus $5.5 million for Q2 2025 and $5.3 million for Q1 2025.